In summary, the discovery that gain-of-function mutations in TRPC6 caused familial forms of FSGS generated significant interest in targeting TRPC6, and perhaps other TRPC family members, to treat glomerular disease processes. The gene discussed is TRPC6; the disease is glomerular disorder.